DOMA Perpetual Nominates Directors to Pacira BioSciences Board

Friday 14th of March 2025 20:05:00

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

March 14, 2023 - FRANKLIN, Mass. - Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative biologics and biosimilar medicines, today confirmed receipt of director nominations from DOMA Perpetual, a long-term focused investment partnership.

The nominations, which were submitted to Pacira BioSciences' Board of Directors, are for three highly qualified individuals with significant experience in the life sciences industry. The nominees are:

Dr. John H. Johnson, a renowned expert in the field of pain management and a former executive at a leading pharmaceutical company.
Dr. Lisa M. Reisman, a seasoned biotechnology executive with a strong track record of driving growth and innovation in the industry.
Mr. David J. H. Clark, a seasoned investor and entrepreneur with a deep understanding of the life sciences sector.

Pacira BioSciences' Board of Directors will carefully consider the nominations and make a determination regarding the suitability of the nominees to join the Board. The company will provide an update on the nomination process in due course.

"We appreciate the interest of DOMA Perpetual in Pacira BioSciences and the opportunity to consider their nominees for our Board," said Dave Goldberg, President and CEO of Pacira BioSciences. "We will thoroughly review the nominations and make a decision that is in the best interests of our shareholders and the company as a whole."